Eterna Therapeutics Stock (NASDAQ:ERNA)

Revenue Ownership Financials Chart

Previous Close

$1.95

52W Range

$1.71 - $29.25

50D Avg

$2.47

200D Avg

$5.65

Market Cap

$14.06M

Avg Vol (3M)

$77.03K

Beta

6.80

Div Yield

-

ERNA Company Profile

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Aug 29, 1991

Website

ERNA Performance

ERNA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$582.00K	$68.00K	-
Operating Income	$-15.67M	$-21.14M	$-33.22M
Net Income	$-44.55M	$-21.67M	$-24.58M
EBITDA	$-15.67M	$-19.93M	$-33.22M
Basic EPS	$-3.26	$-4.08	$-8.06
Diluted EPS	$-3.26	$-4.08	$-8.06

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
PHVS	Pharvaris N.V.
ANNX	Annexon, Inc.
ITOS	iTeos Therapeutics, Inc.
ENTO	Entero Therapeutics, Inc.
REVB	Revelation Biosciences, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.
BIAF	bioAffinity Technologies, Inc.